The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Jul 24, 2026
· 5 min read
AI Analyzed
View full audit trail →
How do you judge the real value of a new Alzheimer’s drug?
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.000 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.040
8,116 articles tracked
7-day bias trend
LcenterR
Article Excerpt
OPINION
How do you judge the real value of a new Alzheimer’s drug?
ANDRÉ PICARD
HEALTH COLUMNIST
PUBLISHED 1 HOUR AGO
Open this photo in gallery:
A woman receives Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo. The Canadian Drug Expert Committee has shifted their stance, and is recommending that lecanemab should be publicly funded with conditions.
KOTA KIRIYAMA/REUTERS
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
An expert committee at Canada’s Drug Agency has ch…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jul 24, 2026